






Purpose: The purpose of this study was to report the authors’ experience with external ven-
tricular drainage (EVD) before endovascular treatment (EVT) in patients with acute aneurysmal 
subarachnoid hemorrhage (aSAH) and to investigate its relation to hemorrhagic complications.
Materials and Methods: Between March 2010 and December 2017, a total of 122 patients 
were recruited who had an aSAH, underwent EVT to secure the ruptured aneurysm, and had 
EVD performed within 72 hours of rupture. The pre-embo EVD group (n=67) comprised pa-
tients who underwent EVD before EVT, and the post-embo EVD group (n=55) comprised those 
who underwent EVD after EVT.
Results: Overall, EVD-related hemorrhage occurred in 18 patients (14.8%): six (8.9%) in the 
pre-embo EVD group and 12 (21.8%) in the post-embo EVD group (P=0.065). No rebleeding 
occurred between EVD and EVT in the pre-embo EVD group. Clinical outcomes at discharge 
did not differ significantly between groups (P=0.384). At discharge, the final modified Rankin 
Scale score in patients who experienced pre-embo rebleeding was better in the pre-embo 
EVD group than in the post-embo EVD group (P=0.041). Current use of an antiplatelet agent or 
anticoagulant on admission (odds ratio [OR], 2.928; 95% confidence interval [CI], 1.234–7.439; 
P=0.042) and stent use (OR, 2.430; 95% CI, 1.524–7.613; P=0.047) remained independent risk 
factors for EVD-related hemorrhagic complications.
Conclusion: EVD before EVT in patients with aSAH in acute period did not increase the rate 
of rebleeding as well as EVD-related hemorrhagic complications. Thus, performing EVD before 
EVT may be beneficial by normalizing increased intracranial pressure. Especially in patients with 
rebleeding before the ruptured aneurysm is secured, pre-embo EVD may improve clinical out-
comes at discharge.
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INTRODUCTION
Endovascular treatment (EVT) in patients with acute aneurys-
mal subarachnoid hemorrhage (aSAH) carries different risks 
than EVT of unruptured intracranial aneurysms, such as for 
acute hydrocephalus. External ventricular drainage (EVD) is 
one of the most important and common emergency proce-
dures in neurosurgery mainly used to normalize or monitor 
intracranial pressure (ICP).1-3 Increased ICP should be normal-
ized as soon as possible. Patients with aSAH have undergone 
EVT, but EVD has been suggested as a potential risk factor for 
hemorrhagic complications.4-7 When to perform EVD, before 
or after securing the ruptured aneurysm, remains controver-
sial. EVD before EVT may increase rebleeding while EVD after 
EVT may delay normalizing increased ICP. Thus, the purpose 
of this study was to report the authors’ experience with EVD 
before EVT in patients with acute aSAH and to investigate its 
relation to hemorrhagic complications.
MATERIALS AND METHODS
Patient selection
The institutional review board of our institute approved re-
search protocols, and informed consent was waived. A pro-
spective database contained a series of 1,393 patients with 
ruptured intracranial aneurysms treated by microsurgery 
or EVT between March 2007 and December 2017. Among 
them, EVD was performed for 468 patients. A total of 122 
patients were included in this study, and all patients met the 
following criteria: 1) presence of aSAH, 2) underwent EVT to 
secure the ruptured aneurysm within 72 hours of rupture, 
and 3) EVD performed within 72 hours of rupture. Three hun-
dred forty-six patients were excluded due to the following 
reasons: 1) patients underwent microsurgery for securing the 
ruptured aneurysm (n=136); 2) patients underwent EVT more 
than 72 hours after rupture (n=55); 3) patients had a signifi-
cant intracerebral hematoma due to the ruptured aneurysm 
requiring evacuation (n=42); 4) dissecting, fusiform, or blood 
blister-like aneurysm (n=60); 5) mycotic aneurysm (n=6); 6) 
traumatic pseudoaneurysm (n=9); and 7) incomplete clinical 
or radiographic information (n=38). The included patients 
were sorted into two groups: a pre-embo EVD group (n=67) 
comprising patients who underwent EVD before EVT and a 
post-embo EVD group (n=55) comprising those who under-
went EVD after EVT.
Rebleeding was defined as sudden clinical deterioration 
with evidence of fresh blood on a computed tomography 
A B
Fig. 1. External ventricular drainage-related hemorrhage along the ventricular catheter tract. (A) Small, asymptomatic hemorrhage and (B) 
symptomatic parenchymal hemorrhage requiring evacuation.
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(CT) scan in comparison with a previous scan or as evidence 
of contrast leaking on CT angiography (CTA) or digital sub-
traction angiography. Thromboembolic complications were 
defined as angiographic evidence of thrombosis during or 
at the end of EVT. Hemorrhagic complications were defined 
as a newly developed hemorrhage on CT or magnetic reso-
nance image within 30 days after the procedure. EVD-related 
hemorrhagic complication was determined by two indepen-
dent investigators. Regardless of clinical symptoms, hemor-
rhage was considered to be EVD-related if it occurred along 
the ventricular catheter tract after EVD placement (Fig. 1).
External ventricular drainage and endovascular 
treatment
After initial CT and CTA confirmed aSAH, patients with acute 
hydrocephalus, intraventricular hemorrhage, or rapid deterio-
ration of consciousness suggesting increased ICP underwent 
EVD. A hand drill with a 4.6-mm or 5.3-mm drill bit was used 
to perform EVD on Kocher’s point or the supraorbital point 
in patients who were intubated with artificial ventilation un-
der analgosedation using fentanyl, midazolam, morphine, or 
propofol. EVD was drained intermittently, to reach an ICP of 
20 cmH2O (slightly above normal ICP).
The decision to treat a ruptured aneurysm was made by 
agreement of microvascular neurosurgeons and neurointer-
ventionists. All procedures were performed under general 
anesthesia with a standard approach from the common 
femoral artery. A 6- or 7-Fr guiding catheter was positioned 
in the internal carotid artery for anterior circulation aneu-
rysms. A 5- or 6-Fr guiding catheter was positioned in the 
vertebral artery for posterior circulation aneurysms. Coils and 
stents were chosen according to the surgeon’s preference. 
Heparin was not injected intravenously or subcutaneously 
but was instead mixed into saline flushes during the proce-
dure. Therefore, the activated clotting time was not checked 
during the procedure. When stents were used, loading doses 
of clopidogrel (300–600 mg) and aspirin (200–400 mg) were 
given via a nasogastric tube after the femoral artery punc-
ture or deploying stents. After the procedure, patients were 
prescribed 75 mg clopidogrel daily for 3 months and 100 mg 
aspirin daily for at least 12 months. During the procedure, 
1 mg of glycoprotein IIb/IIIa antagonist (tirofiban) was inject-
ed intra-arterially when the parent artery was occluded by a 
thromboembolism. Patients who underwent EVT without a 
stent did not take antiplatelet agents during or after the pro-
cedure.
Clinical and radiographic outcomes
Clinical outcomes and radiographic data were reviewed ret-
rospectively. Patient factors (age, sex, hypertension, diabetes, 
smoking, dyslipidemia, coronary artery disease, antiplatelet 
regiment on admission, anticoagulant regiment on admis-
sion, initial Hunt-Hess grade, initial intracerebral hemorrhage, 
initial intraventricular hemorrhage, initial hydrocephalus, 
pre-embo rebleeding, and symptomatic vasospasm) and 
aneurysm characteristics (location [anterior or posterior cir-
culation], aneurysm dome size [maximal diameter], neck size, 
aneurysm type [saccular or non-saccular], and stents use) 
were evaluated to identify risk factors for EVD-related hemor-
rhagic complications. Clinical outcomes were assessed with 
the modified Rankin scale (mRS) and evaluated by an inde-
pendent investigator who was not involved in patient care. 
A favorable outcome was defined as mRS 0–2 and an unfa-
vorable outcome was defined as mRS 3–6. The radiographic 
data were evaluated by two independent investigators.
Statistical analysis
All statistical analyses were performed with IBM SPSS Statis-
tics version 22.0 (IBM, Armonk, NY, USA) in consultation with 
a biostatistician. Mann-Whitney U test was used for numeric 
variables. Chi-square test or Fisher exact test were used for 
nominal variables. Univariate analysis was performed to 
determine the association of EVD-related hemorrhage with 
other factors. Multivariate logistic regression was performed 
on variables with an unadjusted effect, and a P-value less 
than 0.10 on univariate analysis was used to determine risk 
factors independently associated with EVD-related hemor-
rhagic complications. A P-value less than 0.05 for a 95% con-
fidence interval (CI) was considered statistically significant.
 
RESULTS
The radiographic characteristics and clinical outcomes of 
the 122 patients in both groups are shown in Table 1. Mean 
age was 56.5±12.4 years in the pre-embo EVD group and 
58.8±13.3 years in the post-embo EVD group (P=0.527). Ini-
tial Hunt-Hess grade differed significantly between groups 
(P=0.034). The pre-embo EVD group had more patients with 
a poor grade. Nineteen patients (28.4%) in the pre-embo 
EVD group and eight (14.5%) in the post-embo EVD group 
had initial intracerebral hemorrhage (P=0.094). Rebleeding 
before EVT seemed more common in the pre-embo EVD 
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group (28.4%) than in the post-embo EVD group (41.8%), 
but the difference was not statistically significant (P=0.120). 
Anterior circulation aneurysms were more common than 
posterior circulation aneurysms. Mean aneurysm size and 
neck size were 6.5±1.5 and 3.1±0.9, respectively, and did not 
differ between groups. Overall, EVD-related hemorrhage oc-
curred in 18 patients (14.8%): six (8.9%) in the pre-embo EVD 
group and 12 (21.8%) in the post-embo EVD group (P=0.065). 
Three patients (one in the pre-embo EVD group and two in 
the post-embo EVD group) had symptomatic parenchymal 
hemorrhage requiring surgical evacuation. The other pa-
tients had small, asymptomatic hemorrhage along the ven-
Table 1. Clinical and radiographic characteristics of two groups
Total (n=122) Pre-embo EVD (n=67) Post-embo EVD (n=55) P-value
Age (years) 57.2±12.9 56.5±12.4 58.8±13.3 0.527*
Female 92 (75.4) 49 (73.1) 43 (78.2) 0.674 
Hypertension 44 (36.1) 27 (40.3) 17 (30.9) 0.286 
Diabetes 24 (19.7) 12 (17.9) 12 (21.8) 0.428 
Smoking 22 (18.0) 10 (14.9) 12 (21.8) 0.327 
Dyslipidemia 25 (20.5) 15 (22.4) 10 (18.2) 0.452 
Coronary artery disease 9 (7.4) 5 (7.5) 4 (7.3) 0.893 
Antiplatelet agent on admission 15 (12.3) 9 (13.4) 6 (10.9) 0.734 
Anticoagulant on admission 5 (4.1) 3 (4.5) 2 (3.6) 0.682 
Initial Hunt-Hess grade 0.034 
  Grade 1 0 (0) 0 (0) 0 (0)
  Grade 2 2 (1.6) 0 (0) 2 (3.6)
  Grade 3 16 (13.1) 5 (7.5) 11 (20.0)
  Grade 4 69 (56.6) 35 (52.2) 34 (61.8)
  Grade 5 35 (28.7) 27 (40.3) 8 (14.5)
Initial intracerebral hemorrhage 27 (22.1) 19 (28.4) 8 (14.5) 0.094 
Initial intraventricular hemorrhage 88 (72.1) 46 (68.7) 42 (76.4) 0.152 
Initial hydrocephalus 55 (45.1) 32 (47.8) 23 (41.8) 0.314 
Pre-embo rebleeding 42 (34.4) 19 (28.4) 23 (41.8) 0.120 
Aneurysm location 0.296 
  Anterior circulation 95 (77.9) 54 (80.6) 41 (74.5)
  Posterior circulation 27 (22.1) 13 (19.4) 14 (25.5)
Aneurysm size (mm) 6.5±1.5 6.4±1.3 6.8±1.6 0.312*
Neck size (mm) 3.1±0.9 3.4±1.1 2.9±1.2 0.384*
Aneurysm type 0.622 
  Saccular 95 (77.9) 51 (76.1) 44 (80.0)
  Non-saccular 27 (22.1) 16 (23.9) 11 (20.0)
Stents use 40 (32.8) 24 (35.8) 16 (29.1) 0.272 
EVD-related hemorrhage 18 (14.8) 6 (8.9) 12 (21.8) 0.065 
Symptomatic vasospasm 22 (18.0) 12 (17.9) 10 (18.2) 0.848 
Outcomes at discharge 0.384 
  Favorable (mRS 0-2) 32 (26.2) 19 (28.4) 13 (23.6)
  Unfavorable (mRS 3-6) 90 (73.8) 48 (71.6) 42 (76.4)
Values are presented as mean±standard deviation or number (%).
EVD, external ventricular drainage; mRS, modified Rankin scale.
*According to Student t-tests.
https://doi.org/10.5469/neuroint.2018.01067
Lim YC et al. EVD before EVT
39
tricular catheter tract. No rebleeding occurred between EVD 
and EVT in the pre-embo EVD group.
Logistic regression adjusted for age and sex showed that 
antiplatelet or anticoagulant use on admission (odds ratio 
[OR], 2.928; 95% CI, 1.234–7.439; P=0.042) and stent use (OR, 
2.430; 95% CI, 1.524–7.613; P=0.047) remained independent 
risk factors for EVD-related hemorrhagic complications (Ta-
ble 2). Aneurysm neck size, aneurysm type, and EVD timing 
Table 2. Risk factors for EVD-related hemorrhagic complications
Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
Age in years
  <57 1 1
  ≥57 1.305 (0.438–4.226) 0.659 1.156 (0.461–3.594) 0.713
Gender
  Female 1 1
  Male 1.219 (0.778–5.061) 0.538 1.288 (0.647–4.871) 0.622
Hypertension 2.280 (0.635–4.782) 0.636
Diabetes 1.587 (0.716–3.344) 0.486
Smoking 0.930 (0.308–2.904) 0.585
Dyslipidemia 1.262 (0.648–3.742) 0.725
Coronary artery disease 1.443 (0.840–4.622) 0.147
Antiplatelet or anticoagulation 3.142 (1.483–6.570) 0.038 2.928 (1.234–7.439) 0.042
  Use on admission
Initial Hunt-Hess grade
  Good (grade 1, 2, or 3) 1
  Poor (grade 4 or 5) 2.794 (0.89– 6.737) 0.108
Initial intracerebral hemorrhage 0.741 (0.336–1.087) 0.214
Initial intraventricular hemorrhage 1.535 (0.827–3.134) 0.369
Initial hydrocephalus 0.893 (0.552–1.213) 0.301
Aneurysm location
  Anterior circulation 1
  Posterior circulation 2.008 (0.921–4.831) 0.223
Aneurysm size (mm)
  <6.5 1
  ≥6.5 0.826 (0.783–1.093) 0.553
Neck size (mm)
  <3.1 1
  ≥3.1 1.569 (0.920–2.344) 0.098 1.785 (0.823–4.311) 0.236
Aneurysm type
  Saccular 1 1
  Non-saccular 2.779 (0.997–4.540) 0.052 2.252 (0.854–7.785) 0.089
Stent use 2.846 (1.815–5.906) 0.041 2.430 (1.524–7.613) 0.047
EVD timing
  Pre-embo 1 1
  Post-embo 2.797 (0.925–7.503) 0.088 2.150 (0.812–8.857) 0.154
EVD, external ventricular drainage; CI, confidence interval; OR, odds ratio.
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(pre- vs. post-embo) had P-values of 0.098, 0.052, and 0.088, 
respectively, in a simple logistic regression but were not 
statistically significant after adjustment (P=0.236, 0.089, and 
0.154, respectively). EVD timing (pre- vs. post-embo) was 
not a risk factor for EVD-related hemorrhagic complications, 
suggesting that pre-embo EVD did not increase EVD-related 
hemorrhagic complications compared to post-embo EVD.
Clinical outcomes at discharge did not differ significantly 
between groups (P=0.384). Overall, 32 patients (26.2%) had 
favorable outcomes and 90 (73.8%) had unfavorable out-
comes at discharge. Clinical outcome at discharge, adjusted 
for age, sex, and initial Hunt-Hess grade, in patients who had 
pre-embo rebleeding (19 in the pre-embo EVD group and 23 
in the post-embo EVD group) were better in the pre-embo 
EVD group than in the post-embo EVD group (P=0.041; Fig. 2).
DISCUSSION
In our small series, EVD-related hemorrhagic complica-
tions occurred in 14.8% of patients. Although EVD-related 
hemorrhage seemed more common in post-embo EVD 
(21.8%) than in pre-embo EVD (8.9%), the difference was not 
statistically significant (P=0.065). In addition, no rebleeding 
occurred due to pre-embo EVD in our series, suggesting that 
pre-embo EVD did not increase hemorrhagic complications, 
such as rebleeding or EVD-related hemorrhage. EVD-re-
lated hemorrhage rates of 15–20% have been reported in 
patients with aSAH.8,9 Data regarding the risk of rebleeding 
after EVD in patients with an unprotected aneurysm remains 
conflicting. Hasan et al.6 prospectively studied 473 patients 
and reported that the rebleeding rate within 12 days of aSAH 
was significantly higher in patients with EVD (43%) than in 
those without (15%, P=0.025). However, the authors did not 
provide information on EVD timing.6 Paré et al.7 reported on 
a cohort of 128 patients with aSAH. Patients with EVD (30%) 
had a higher incidence of rebleeding than those without (8%, 
P<0.006). A retrospective study of 304 patients with aSAH 
demonstrated no difference in rebleeding rates among pa-
tients with (4.4%) or without EVD (5.4%).10 Another study also 
concluded that EVD was not associated rebleeding in pa-
tients with aSAH.11 Hellingman et al.5 reported no difference 
between the incidence of rebleeding with preoperative 
EVD (21%) and controls (21%) in a study of 546 prospectively 
recruited patients with aSAH. However, previous studies did 
not account for time gap between EVD and aneurysm treat-
ments. Additionally, the interval between onset of aSAH and 
EVD was vague. In the present study, thus, we tried to assess 
the safety of EVD placement before securing ruptured aneu-
rysms in the acute period and to emphasize that controlling 
increased ICP is more important in such patients to improve 
clinical outcomes. In the same context, we found that clinical 
outcomes at discharge were better in the pre-embo EVD 
group than in the post-embo EVD group, suggesting that 
pre-embo EVD improved clinical outcomes by controlling 
ICP. Securing a ruptured aneurysm before EVD in patients 
with increased ICP may delay normalizing ICP and induce 
brain damage.
Among 468 patients who underwent EVD, pre-embo re-
bleeding occurred in 45 patients (9.6%). In our practice, we 
tend to perform EVT rather than microsurgery in patients 
with pre-embo rebleeding, including 42 of the 45 patients in 
Fig. 2. Clinical outcomes (mRS) for two groups of patients who experienced pre-embo rebleeding at discharge (P=0.041). mRS, modified 
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the present study. A good initial Hunt-Hess grade was more 
common in the post-embo EVD group (P=0.034) than in the 
pre-embo EVD group because we performed one-staged 
coiling immediately followed by EVD if rebleeding occurred.
Patients who undergo EVT for aSAH need antiplatelet 
agents, anticoagulant agents, or both to prevent potential 
thromboembolic complications. Consequently, hemorrhagic 
complications can occur if patients with acute aSAH require 
additional surgical procedures after EVT. We identified two 
risk factors for EVD-related hemorrhagic complications: 
stent use and antiplatelet or anticoagulant use on admis-
sion. These risk factors are not surprising because physicians 
who treat intracranial aneurysms know that they are related 
to bleeding tendency. If stent use is considered to require 
antiplatelet use, both risk factors have same mechanism to 
provoke hemorrhagic complications. In our previous study of 
stent-assisted coil embolization in patients with acute aSAH, 
EVD was the only independent risk factor for periprocedural 
complications in a multivariate logistic regression.12 Bruder et 
al.13 analyzed the rate of EVD-related hemorrhage in patients 
with aSAH with or without artificial anticoagulation therapy 
during aneurysm treatment. EVD-related hemorrhage oc-
curred in 12% of patients with aSAH. The rate of EVD-related 
hemorrhage in patients with additional anticoagulation after 
securing aneurysm was 24% versus 8% in patients without 
anticoagulation (P<0.001).13 In our practice, heparin was not 
injected intravenously or subcutaneously but was instead 
mixed into saline flushes during the procedure because we 
felt that hemorrhagic complications were more fatal than 
thromboembolic complications in patients with aSAH. If 
thromboembolism occurred during the procedure, we in-
jected up to 1 mg of glycoprotein IIb/IIIa antagonist (tirofiban) 
intra-arterially.
This study has several limitations. It is a retrospective study 
and included a small number of patients, which lowers 
the power to identify the true incidence of EVD-related 
complications. The individual response to each antiplatelet 
agent was not evaluated. A study on coronary intervention 
suggested that 30% of patients have relative clopidogrel 
resistance.14 Thus, a subset of patients probably over- or un-
der-responded to antiplatelet agents. Comparison of clinical 
outcomes between groups of patients with aSAH should 
be adjusted for well-known predisposing or risk factors. In 
the present study, clinical outcomes for two groups of pa-
tients who experienced pre-embo rebleeding in Fig. 2 was 
adjusted for age, sex, and initial Hunt-Hess grade. However, 
comparison of overall clinical outcomes at discharge be-
tween groups in Table 1 was not adjusted for those factors. 
It might show different results if adjusted because the initial 
Hunt-Hess grade was significantly different between two 
groups. Finally, we did not assess activity of the coagulation 
cascade. An individual’s potential to generate thrombin may 
correlate closely with a hypercoagulable state, which may 
have supported our results. Therefore, monitoring changes 
in prothrombin time, partial thromboplastin time, or throm-
bin generation15 may help predict EVD-related hemorrhagic 
complications.
CONCLUSION
EVD before EVT in patients with aSAH in the acute period 
did not increase the rate of rebleeding or EVD-related hem-
orrhagic complications. Thus, performing EVD before EVT 
may be beneficial to normalize increased ICP. Especially in 
patients with rebleeding before a ruptured aneurysm is 
secured, pre-embo EVD may improve clinical outcomes at 
discharge.
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